Development of predictive models for airflow obstruction in alpha-1-antitrypsin deficiency

American Journal of Epidemiology

Volumn 170, Issue 8, 2009, Pages 1005-1013

  Castaldi, P J ^a   Demeo, D L ^a   Kent, D M ^a   Campbell, E J ^a   Barker, A F ^a   Brantly, M L ^a   Eden, E ^a   McElvaney, N G ^a   Rennard, S I ^a   Stocks, J M ^a   Stoller, J K ^a   Strange, C ^a   Turino, G ^a   Sandhaus, R A ^a   Griffith, J L ^a   Silverman, E K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Alpha 1 antitrypsin deficiency; Genetics; Polymorphism, single nucleotide; Pulmonary disease, chronic obstructive

Indexed keywords

BRONCHODILATING AGENT; PROTEINASE INHIBITOR; RAUWOLFIA ALKALOID;

AIRFLOW; DISEASE SEVERITY; DISEASE TREATMENT; ENZYME ACTIVITY; GENETIC ANALYSIS; GENETICS; GENOTYPE; HEALTH RISK; POLYMORPHISM; SYMPTOM;

ADULT; AGE; AIRWAY OBSTRUCTION; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; FAMILY STUDY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MODEL; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

AIRWAY RESISTANCE; ALPHA 1-ANTITRYPSIN DEFICIENCY; FEMALE; FORCED EXPIRATORY VOLUME; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING;

EID: 70349696529     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwp216     Document Type: Article

References (38)

1. Lieberman J, Winter B, Sastre A. Alpha 1-antitrypsin Pi-types in 965 COPD patients. Chest. 1986;89(3):370-373.
2. Silverman EK, Miletich JP, Pierce JA, et al. Alpha-1-antitrypsin deficiency. High prevalence in the St. Louis area determined by direct population screening. Am Rev Respir Dis. 1989;140(4): 961-966.
3. Luisetti M, Seersholm N. a1-Antitrypsin deficiency. 1: epidemiology of a1-antitrypsin deficiency. Thorax. 2004;59(2): 164-169.
4. Eriksson S. A 30-year perspective on a1-antitrypsin deficiency. Chest. 1996;110(6 suppl):237S-242S.
5. Silverman EK, Province MA, Campbell EJ, et al. Family study of alpha 1-antitrypsin deficiency: effects of cigarette smoking, measured genotype, and their interaction on pulmonary function and biochemical traits. Genet Epidemiol. 1992;9(5): 317-331.
6. DeMeo DL, Sandhaus RA, Barker AF, et al. Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency. Thorax. 2007;62(9):806-813.
7. Silverman EK, Province MA, Campbell EJ, et al. Variability of pulmonary function in alpha-1-antitrypsin deficiency: residual family resemblance beyond the effect of the Pi locus. Hum Hered. 1990;40(6):340-355.
8. Rodriguez F, de la Roza C, Jardi R, et al. Glutathione Stransferase P1 and lung function in patients with a1-antitrypsin deficiency and COPD. Chest. 2005;127(5):1537-1543.
9. Stoller JK, Aboussouan LS. a1-Antitrypsin deficiency. Lancet. 2005;365(9478):2225-2236.
10. Ferris BG. Epidemiology Standardization Project (American Thoracic Society). Am Rev Respir Dis. 1978;118(6): 1-120.
11. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med. 1995;152(3): 1107-1136.
12. DeMeo DL, Campbell EJ, Barker AF, et al. IL10 polymorphisms are associated with airflow obstruction in severe a1- antitrypsin deficiency. Am J Respir Cell Mol Biol. 2008;38(1): 114-120.
13. Novoradovsky A, Brantly ML, Waclawiw MA, et al. Endothelial nitric oxide synthase as a potential susceptibility gene in the pathogenesis of emphysema in a1-antitrypsin deficiency. Am J Respir Cell Mol Biol. 1999;20(3):441-447.
14. de Bakker PI, Yelensky R, Pe'er I, et al. Efficiency and power in genetic association studies. Nat Genet. 2005;37(11): 1217-1223.
15. O'Connell JR, Weeks DE. PedCheck: a program for identification of genotype incompatibilities in linkage analysis. Am J Hum Genet. 1998;63(1):259-266.
16. Piitulainen E, Eriksson S. Decline in FEV1 related to smoking status in individuals with severe a1-antitrypsin deficiency (PiZZ). Eur Respir J. 1999;13(2):247-251.
17. Eden E, Hammel J, Rouhani FN, et al. Asthma features in severe a1-antitrypsin deficiency: experience of the National Heart, Lung, and Blood Institute Registry. Chest. 2003;123(3): 765-771.
18. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of a1-antitrypsin. Am J Respir Crit Care Med. 1998; 158(1):49-59.
19. Hutchison DC, Cooper D. British Thoracic Society. Alpha-1- antitrypsin deficiency: smoking, decline in lung function and implications for therapeutic trials. Respir Med. 2002;96(11): 872-880.
20. Gauderman WJ. Sample size requirements for association studies of gene-gene interaction. Am J Epidemiol. 2002; 155(5):478-484.
21. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837-1847.
22. Selker HP, Griffith JL, Beshansky JR, et al. Patient-specific predictions of outcomes in myocardial infarction for real-time emergency use: a thrombolytic predictive instrument. Ann Intern Med. 1997;127(7):538-556.
23. Kücxükaycan M, Van Krugten M, Pennings HJ, et al. Tumor necrosis factor-a + 489G/A gene polymorphism is associated with chronic obstructive pulmonary disease. Respir Res. 2002;3(1):29.
24. Gingo MR, Silveira LJ, Miller YE, et al. Tumour necrosis factor gene polymorphisms are associated with COPD. Eur Respir J. 2008;31(5):1005-1012.
25. Hegab AE, Sakamoto T, SaitohW, et al. Polymorphisms of TNFa, IL1b, and IL1RN genes in chronic obstructive pulmonary disease. Biochem Biophys Res Commun. 2005;329(4):1246-1252.
26. Hsieh MH, Chong IW, Hwang JJ, et al. Lack of associations between several polymorphisms in cytokine genes and the risk of chronic obstructive pulmonary diseases in Taiwan. Kaohsiung J Med Sci. 2008;24(3):126-137.
27. Janciauskiene SM, Nita IM, Stevens T. a1-Antitrypsin, old dog, new tricks. a1-Antitrypsin exerts in vitro anti-inflammatory activity in human monocytes by elevating cAMP. J Biol Chem. 2007;282(12):8573-8582.
28. Cohen N, Flamenbaum W. Obesity and hypertension. Demonstration of a "floor effect." Am J Med. 1986;80(2):177-181.
29. Dockery DW, Speizer FE, Ferris BG Jr, et al. Cumulative and reversible effects of lifetime smoking on simple tests of lung function in adults. Am Rev Respir Dis. 1988;137(2):286-292.
30. Vineis P, Schulte P, McMichael AJ. Misconceptions about the use of genetic tests in populations. Lancet. 2001;357(9257): 709-712.
31. Holtzman NA, Marteau TM. Will genetics revolutionize medicine? N Engl J Med. 2000;343(2):141-144.
32. Bell J. The new genetics in clinical practice. BMJ. 1998; 316(7131):618-620.
33. Pharoah PD, Antoniou AC, Easton DF, et al. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med. 2008;358(26):2796-2803.
34. Samani NJ, Erdmann J, Hall AS, et al. Genomewide association analysis of coronary artery disease. N Engl J Med. 2007; 357(5):443-453. (Pubitemid 47204873)
35. Botto LD, Khoury MJ. Commentary: facing the challenge of gene-environment interaction: the two-by-four table and beyond. Am J Epidemiol. 2001;153(10):1016-1020.
36. Hunter DJ, Altshuler D, Rader DJ. From Darwin's finches to canaries in the coal mine-mining the genome for new biology. N Engl J Med. 2008;358(26):2760-2763.
37. Reilly JJ. COPD and declining FEV1-time to divide and conquer? N Engl J Med. 2008;359(15):1616-1618.
38. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD)Workshop summary. Am J Respir Crit Care Med. 2001;163(5):1256-1276.